Skip to main content
. Author manuscript; available in PMC: 2022 Jun 8.
Published in final edited form as: Vaccine. 2021 May 18;39(25):3379–3387. doi: 10.1016/j.vaccine.2021.04.063

Table 2.

Comparison of quality metrics assessed for purified BG505 DS-SOSIP.664 material from two 50 L GLP and one 250 L cGMP bioreactor runs*.

Attribute 50 L Run 1 (Tox Lot) 50 L Run 2 250 L cGMP Run (Phase 1)
Yield (total amount of purified trimer, g) 3.4 4.0 9.6
Concentration 0.57 mg/mL 0.59 mg/mL 0.506 mg/mL
Purity by SEC (% Main Peak) 99.74% 99.4% 100%
Residual host cell protein < 150 ng/mL (< 263 ppm) < 30 ng/mL < 30 ng/mL
Residual DNA < 30 pg/mL < 6.0 pg/mL < 6 pg/mL
Endotoxin < 8.8e-5 EU/μg < 8.8e-5 EU/μg < 0.0001 EU/μg
Bioburden 0 CFU/10 mL 0 CFU/10 mL 0 CFU/10 mL
PH 7.24 7.30 7.20
Appearance Clear, colorless, no visible particles Clear, colorless, no visible particles Clear, colorless, no turbidity; essentially free of particulates
Protein Mass (SEC-MALS) 215 kDa 213 kDa 203 kDa
Glycan Mass (SEC-MALS) 129 kDa 128 kDa 122 kDa
PS80 < 15 ppm < 15 ppm < 15 ppm
TnBP < 3 ug/mL < 3 ug/mL < 3 ug/mL
Melting temperature (Tm) by DSC 77.0 76.7 77.3
*

Abbreviations include SEC: Size exclusion chromatography, SEC-MALS: Size exclusion chromatography-multi angle light scattering, PS80: polysorbate 80, TnBP: Tri-n-butyl phosphate, DSC: Differential scanning calorimetry, EU: endotoxin units, CFU: colony forming units, GLP: Good laboratory practices, cGMP: current good manufacturing practices.

Actual output, accounting for large volume in-process sampling to suffice IND-enabling studies.